A recent study found an investigational topical therapy, SB206 (berdazimer sodium gel co-administered with hydrogel), effectively treated molluscum contagiosum with good tolerability.
While there are a variety of treatment options for molluscum contagiosum, none have been well-studied or approved by the FDA, the researchers said.
They compared the efficacy and tolerability of topical SB206 in a 12-week, multicenter, phase 2, randomized, double-blind, vehicle-controlled clinical trial. A total of 256 participants (mean age 7 years) were randomized to either twice-daily or once-daily topical SB206 or vehicle.
You may also like...
Molluscum Contagiosum in Atopic Dermatitis
Measles Outbreak 101: What Dermatologists Need to Know
Among the 217 participants who completed the full 12 weeks of treatment, the researchers found all molluscum contagiosum lesions cleared in 13.2%, 41%, and 35.2% of participants treated with either 4%, 8%, or 12% twice-daily SB206, respectively, and 41.9% of those treated with once-daily 12% SB206 compared with 20% of those treated with vehicle.
In participants treated with SB206, application-site erythema occurred in 10.6%, the researchers observed. Application site reactions were the most common adverse events that led to treatment discontinuation, they added, and affected 2 participants in each twice-daily SB206 treatment group compared with 0 participants in the vehicle and SB206 12% once-daily group.
“Of the doses studied, SB206 12% applied once daily provided the best balance between [molluscum contagiosum] lesion clearance and tolerability,” the researchers concluded. “A larger study is needed to confirm [once-daily] SB206 12% efficacy and provide additional safety assessments.”
Hebert AA, Siegfried EC, Durham T, et al. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial [published online October 3, 2019]. J Am Acad Dermatol. doi:10.1016/j.jaad.2019.09.064